HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

CTFA will submit an application to establish a United States Pharmacopeia monograph for antimicrobial active ingredient triclocarban on behalf of industry group Interested Party Task Force, association announces. Application is intended to "establish a name for the active ingredient as well as establishing standards for identification and purity" under the monograph, CTFA notes. Triclocarban is currently designated Category III for efficacy under the OTC topical antimicrobial drug products tentative final monograph, but industry is seeking to change its status. Procter & Gamble submitted comments to FDA last year requesting the ingredient be designated Category 1 at levels of up to 1.5% (1"The Rose Sheet" Sept. 1, 2003, p. 6). Comments will be accepted by CTFA until April 15...

You may also be interested in...

Triclocarban 1.5% Category I Antimicrobial Status Sought By P&G

FDA should include triclocarban at levels of up to 1.5% as a Category I ingredient in its OTC topical antimicrobial products final monograph, Procter & Gamble states in Aug. 19 comments to the agency

Expectations Are High For New EMA Boss

Emer Cooke seems set to take over as head of the European Medicines Agency – one of the world's most powerful regulatory bodies – before the end of the year. We report on the reaction of a range of pharmaceutical sector stakeholders to her nomination.

Clif Bar Claims In Google Ads Clipped In Accelerated Review Of Kind Challenge

Clif Bar didn’t convince National Advertising Division a challenge by Kind is too “complex” for the SWIFT forum. NAD attorneys determined Clif didn’t support its claims of sustained energy and “better” performing ability.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts